Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.

From work done largely on derived cell lines, it has been suggested that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) might be a therapeutic target for many forms of malignancy. However, use of primary tumor cells, including chronic lymphocytic leukemic (CLL) cells, has shown inherent resistance to TRAIL. Although the molecular basis for this resistance remains unknown, treatment with histone deacetylase inhibitors (HDACi) often sensitizes resistant cells to TRAIL-induced apoptosis. We used structurally diverse HDACi to ascertain which HDAC needs to be inhibited for the sensitization. Inhibition of HDAC class I but not class II is required for sensitization to TRAIL-induced apoptosis of CLL cells and various cell lines. Using different HDACi together with small interfering RNA for HDAC1, HDAC2, HDAC3, and HDAC6, we report that inhibition of HDAC1 and HDAC2 but not HDAC3, HDAC6, and HDAC8 are primarily responsible for sensitization to TRAIL-induced apoptosis. Based on these data and our previous studies, we propose that a clinical trial in CLL is warranted using a combination of a selective HDACi that inhibits HDAC1 and/or HDAC2 together with a form of TRAIL that signals through TRAIL receptor 1.

[1]  L. Altucci,et al.  Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells , 2005, Nature Medicine.

[2]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[3]  S. Kern,et al.  A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. , 2000, Cancer research.

[4]  Stuart L Schreiber,et al.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. , 2002, Chemistry & biology.

[5]  M. Grever,et al.  The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells , 2004, Leukemia.

[6]  J. Blenis,et al.  FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. , 2000, Immunity.

[7]  S. Inoue,et al.  Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies , 2004, Cell Death and Differentiation.

[8]  Jorge A. Almenara,et al.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. , 2003, Molecular cancer therapeutics.

[9]  J. Neuzil,et al.  Sensitization of mesothelioma to TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL down-regulation. , 2004, Biochemical and biophysical research communications.

[10]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[11]  Ping Zhu,et al.  Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells , 2001, The EMBO journal.

[12]  S. Horinouchi,et al.  In vivo destabilization of dynamic microtubules by HDAC6‐mediated deacetylation , 2002, The EMBO journal.

[13]  Xiao-Fan Wang,et al.  HDAC6 is a microtubule-associated deacetylase , 2002, Nature.

[14]  K. Glaser,et al.  Role of class I and class II histone deacetylases in carcinoma cells using siRNA. , 2003, Biochemical and biophysical research communications.

[15]  Ricardo Macarron,et al.  Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases , 2003, Journal of Pharmacology and Experimental Therapeutics.

[16]  G. Cohen,et al.  Fas-associated Death Domain Protein and Caspase-8 Are Not Recruited to the Tumor Necrosis Factor Receptor 1 Signaling Complex during Tumor Necrosis Factor-induced Apoptosis* , 2003, Journal of Biological Chemistry.

[17]  Ricky W. Johnstone,et al.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer , 2002, Nature Reviews Drug Discovery.

[18]  Minoru Yoshida,et al.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. , 2005, Molecular cell.

[19]  Jorge A. Almenara,et al.  The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. , 2003, Cancer research.

[20]  G. Cohen,et al.  Death receptors leave a caspase footprint that Smacs of XIAP , 2003, Cell Death and Differentiation.

[21]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[22]  S. Grant,et al.  Histone deacetylase inhibitors: insights into mechanisms of lethality , 2005, Expert opinion on therapeutic targets.

[23]  M. Yoshida,et al.  Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[24]  P. Marks,et al.  Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.

[25]  T. Tsuruo,et al.  Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity. , 2001, Cancer research.

[26]  G. Cohen,et al.  Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia , 2002, Oncogene.

[27]  S. Srinivasula,et al.  Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL* , 1997, The Journal of Biological Chemistry.

[28]  A. V. van Kuilenburg,et al.  Histone deacetylases (HDACs): characterization of the classical HDAC family. , 2003, The Biochemical journal.

[29]  A. Ashkenazi,et al.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily , 2002, Nature Reviews Cancer.

[30]  D. Steensma,et al.  On the TRAIL of a new therapy for leukemia , 2005, Leukemia.

[31]  G. Cohen,et al.  Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1 , 2005, Cell Death and Differentiation.

[32]  R. Maestro,et al.  Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)* , 2003, The Journal of Biological Chemistry.

[33]  Minoru Yoshida,et al.  FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. , 2002, Cancer research.

[34]  E. Seto,et al.  Activation of the Growth-Differentiation Factor 11 Gene by the Histone Deacetylase (HDAC) Inhibitor Trichostatin A and Repression by HDAC3 , 2004, Molecular and Cellular Biology.

[35]  G. Cohen,et al.  TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. , 2005, Cancer research.

[36]  Silvio Massa,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[37]  A. Mai,et al.  Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A. , 2003, Journal of medicinal chemistry.

[38]  T. Griffith,et al.  Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[39]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[40]  L. Altucci,et al.  Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. , 2005, Journal of medicinal chemistry.

[41]  M. Peter,et al.  Cytotoxicity‐dependent APO‐1 (Fas/CD95)‐associated proteins form a death‐inducing signaling complex (DISC) with the receptor. , 1995, The EMBO journal.

[42]  Yahong Lin,et al.  TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/DIABLO. , 2002, Genes & development.

[43]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Butterworth,et al.  Bcl-2 and Bcl-xL Inhibit CD95-mediated Apoptosis by Preventing Mitochondrial Release of Smac/DIABLO and Subsequent Inactivation of X-linked Inhibitor-of-Apoptosis Protein* , 2002, The Journal of Biological Chemistry.

[45]  K. Shiraki,et al.  Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis. , 2002, International journal of molecular medicine.

[46]  M. Andreeff,et al.  Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL‐R1 and TRAIL‐R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin‐ and bortezomib‐induced cell death , 2005, British journal of haematology.

[47]  P. Atadja,et al.  Cotreatment with Histone Deacetylase Inhibitor LAQ824 Enhances Apo-2L/Tumor Necrosis Factor-Related Apoptosis Inducing Ligand-Induced Death Inducing Signaling Complex Activity and Apoptosis of Human Acute Leukemia Cells , 2004, Cancer Research.

[48]  S. Kyrylenko,et al.  Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases , 2003, Cellular and Molecular Life Sciences CMLS.

[49]  J. Tschopp,et al.  TRAIL receptor-2 signals apoptosis through FADD and caspase-8 , 2000, Nature Cell Biology.